HealthDay News — During August 2021 to August 2023, only 36.4% of US adults had no cardiovascular disease (CVD) risk factors, according to a September data brief published by the National Center for ...

HealthDay News — The US Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ...

Researchers explored the impact of polypharmacy on long-term treatment response among patients with early rheumatoid arthritis.

North Carolina and Idaho are cutting their Medicaid programs to bridge budget gaps, raising fears that providers will stop taking patients.

Psychosocial symptoms improved with encounters with a behavioral health clinician and psychotropic prescription.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Maxillary sinusitis is characterized by facial pain and pressure in the cheek area that worsens with bending over or lying ...

Helen Tager-Flusberg, director of the Center for Autism Research Excellence at Boston University, called Trump’s comments dangerous. Fevers can harm the mother and the developing fetus, she said, ...

Women with acute stroke are less likely than men to be accurately identified as having a stroke in the prehospital setting, ...

HealthDay News — Louisiana health officials have confirmed a fifth death this year linked to Vibrio vulnificus, a rare and dangerous flesh-eating bacteria found in warm coastal waters.

Vaccination against measles, mumps, rubella, and varicella is typically administered in 2 doses: the first between 12 to 15 months and the second at 4 to 6 years.

The ACHIEVE-3 trial was a 52-week, randomized, open-label study that included 1698 T2D patients inadequately controlled on metformin.